Company Nanoform Finland Oyj Nasdaq Helsinki
Equities
FI4000330972
Biotechnology & Medical Research
Business Summary
Sales per Business
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Nanotechnology and Drug Particle Engineering
100.0
%
| 3 | 100.0 % | 3 | 100.0 % | -26.41% |
Sales per region
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Europe
57.0
%
| 2 | 56.2 % | 1 | 57.0 % | -25.37% |
United States
43.0
%
| 2 | 43.8 % | 1 | 43.0 % | -27.73% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Edward Hæggström
CEO | Chief Executive Officer | 55 | 14-12-31 |
Albert Häggström
DFI | Director of Finance/CFO | 53 | 14-12-31 |
Investor Relations Contact | - | 19-04-30 | |
Antonio da Silva
PRN | Corporate Officer/Principal | 50 | 18-12-31 |
Peter Hänninen
LAW | General Counsel | 36 | 20-08-31 |
David Rowe
PRN | Corporate Officer/Principal | 57 | 18-12-31 |
Christian Jones
PRN | Corporate Officer/Principal | 44 | 17-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 68 | 19-04-01 | |
Mads Laustsen
BRD | Director/Board Member | 67 | 18-12-31 |
Albert Häggström
DFI | Director of Finance/CFO | 53 | 14-12-31 |
Jeanne A. Thoma
BRD | Director/Board Member | 64 | 21-09-30 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 85,445,164 | 59,636,291 ( 69.79 %) | 0 | 69.79 % |
Company contact information
Sector
Sales per region
1st Jan change | Capi. | |
---|---|---|
+26.28% | 48.09B | |
-3.99% | 40.43B | |
+45.32% | 40.62B | |
-6.20% | 28.36B | |
+6.36% | 24.89B | |
-21.47% | 19.01B | |
+27.58% | 12.09B | |
-2.75% | 11.8B | |
-2.02% | 11.88B |